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Poster Session II 167All patients received 1 mg/kg rATG on day -4, then 3 mg/kg/day of
days -3,-2,-1 (total dose 10 mg/kg). Blood samples (n5 14) were ob-
tained from each patient at baseline, 24 hrs post each dose, days
0,11,13,15,17 and weeks 2,4,8,12 and 24. Total rATG by ELISA
and active rATG by FACS were assayed at each time point.Results:
The intersubject variability in Total CL was 50% CV (or 5 range)
and for Active Cl was 70% CV (or 11 range). Total rATG was
measurable in all patients through week 4 and in 11/13 patients at
week 8. Mean day 0 total rATG was 53 mcg/ml (range 22.6–80.7)
and on day 28 was 15.9 mcg/ml (range 5.1–20.6). Active rATG
was measurable in all patients through week 2, 10/13 patients at
week 4 and was undetectable (\0.2 mcg/ml) in 7/13 patients at
week 8. Mean day 0 active rATG was 3.6 mcg/ml (range 0.95–
8.0) and on day 28 was 1.13 mcg/ml (range\0.2–4.64). Median
half-life for total rATG was 27.29 days but could not be reliably es-
timated for active rATG. All patients engrafted by day123 (ANC.
500), and engrafted platelets by day149 (.20K). There were no ep-
isodes of grade 3–4 GVHD; 3 patients developed grade 2 GVHD,
and no grade 3 or 4 adverse rATG related events or serious infec-
tions were observed. Conclusions: When compared to previously
published adult HSCT data and renal transplant data, pediatric pa-
tients have lower total and active rATG levels despite receiving
higher doses. Half lives for total rATG are similar to adult studies.
These data in children suggest differences in initial concentrations
of rATG (total and active) with similar elimination half lives when
compared to adult studies. Differences in patient population,
dose, schedule and sampling make comparisons with prior studies
difficult. Future trials to determine appropriate pediatric doses of
rATG should be performed.474
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Two pediatric dosage guidelines for IV busulfan have been pro-
posed. Nguyen et al (2004) recommend using 5 stratifications based
on actual body weight (\9 kg: 1 mg/kg; 9 to\16 kg: 1.2 mg/kg; 16
to\23 kg: 1.1 mg/kg; 23 to 34 kg: 0.95 mg/kg;.34 kg: 0.8 mg/kg)
while Booth et al (2007) recommend 2 (#12 kg: 1.1 mg/kg;.12 kg:
0.8 mg/kg). This study evaluates the performance of each of these
guidelines by simulating administration of the recommended dose
to children with known busulfan pharmacokinetic parameters.Table 1. Patient’s features and reasons for rejection
Type of SCT planned
Auto-SCT Allo-SCT
Lymphoproli
disorde
n/% Male 157/62% 113/49% 105/63
Median age in
years (range)
49 (10–66) 37.5 (4–64) 46 (18–6
Rejected patients
(%)/Median in months
of time to rejection:
(range)
49 (31%)/4.8
(0.5–13)
24 (21%)/3.2
(0.1–12)
31 (29%)
(0.7–12
Cause of rejection
Progression: n (%) 15 (30.5%) 9 (37.5%) 10 (32%
Insuficient
mobilization:
n (%)
22 (45%) 1 (4%) 13 (42%
Co-morbidity or
death: n (%)
6 (12.5%) 5 (21%) 3 (10%
Patient rejection: n
(%)
5 (10%) 6 (25%) 4 (13%
Other: n (%) 1 (2%) 3 (12.5%) 1 (3%)Health records of children who received IV busulfan prior to
HSCT were reviewed to obtain demographic information, initial
busulfan dose administered, infusion time, and plasma busulfan
concentrations after the initial dose. A minimum of 7 plasma busul-
fan concentrations were available for each patient. Area under the
plasma busulfan concentration vs time curve (AUC) was calculated
using 1-compartmental analysis. Assuming a linear relationship be-
tween dose and AUC, the AUC that would have been achieved after
administration of the busulfan dose indicated by each of the dosage
guidelines was calculated for each child. The proportion of children
who would have achieved an AUC of\900, 900 to 1500 and.1500
mMmin after administration of each of the 2 doses was calculated.
78 children (0.3 to 17.5 years; median: 4.8 years) were included.
Data regarding the AUC achieved after simulated administration
of the proposed busulfan doses are presented below: Neither of
the existing initial IV busulfan pediatric dosing guidelines achieved
an AUC within the target range with sufficient reliability to permit
the use of IV busulfan without determining AUC in each patient.
Under-dosing is more common after administration of doses pro-
posed by Booth et al. Pediatric dosing of IV busulfan requires fur-
ther refinement.Mean AUC AUC\ 900 AUC 5Guidelineferative
rs A
%
5) 4
/4.5
)
19
)
)
)
)mMmin
(±SD)Diag
L/MDS
84/49%
0 (4–64)
(22.5%)/3,7
(0.1–8)
7 (37%)
3 (16%)
4 (21%)
2 (10%)
3 (16%)mMmin
(#;%)nosis
MM
41/49%
56 (32–66)
14 (34%)/6,
(0.5–13.3)
3 (17%)
6 (33.5%)
1 (5.5%)
4 (22%)
0900–1500
mMmin (#;%)Solid
tumors
18/83%
28 (8–48)
3 6 (33%)/2
(0.7–7,5)
4 (66%)
1 (17%)
1 (17%)
0
0AUC . 1500
mMmin (#;%)Booth 2007 1075 ± 336 27* (35) 41 (53) 10 (13)Nguyen 2004 1173 ± 307 14* (18) 50 (64) 14 (18)*p # 0.05.CLINICAL RESEARCH ASSOCIATE – DATA
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ELECTRONIC TOOL TO MANAGE THE TRANSPLANT SCHEDULE
Balsalobre, P., Bun˜o, I., Gayoso, J., Serrano, D., Mun˜oz, C., Gomez-
Pineda, A., Diez-Martin, J.L. Hosp. Gen. Univ. Gregorio Maran˜on,
Madrid, Spain.Other
22/45.5%
32 (20–56)
3 (13.5%)/1
(0.6–1.4)
0
0
2 (66.5%)
1 (33.5%)
0
